Skin microbiome and acne vulgaris: Staphylococcus, a new actor in acne

Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 da...

Full description

Saved in:
Bibliographic Details
Published inExperimental dermatology Vol. 26; no. 9; pp. 798 - 803
Main Authors Dreno, Brigitte, Martin, Richard, Moyal, Dominique, Henley, Jessica B., Khammari, Amir, Seité, Sophie
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.09.2017
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo‐pustular lesions and non‐lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high‐throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under‐representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules (P=.004 and P=.003 respectively) than on non‐lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA‐2 and GEA‐3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic.
AbstractList Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo-pustular lesions and non-lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high-throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under-representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules (P=.004 and P=.003 respectively) than on non-lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA-2 and GEA-3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic.
Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo-pustular lesions and non-lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high-throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under-representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules (P=.004 and P=.003 respectively) than on non-lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA-2 and GEA-3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic.
Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from come-dones, papulo-pustular lesions and non-lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high-throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under-representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, pap-ules and pustules (P=.004 and P=.003 respectively) than on non-lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA-2 and GEA-3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic.
Propionibacterium acnes ( P. acnes ), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo‐pustular lesions and non‐lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high‐throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under‐representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules ( P =.004 and P =.003 respectively) than on non‐lesional skin. Their proportions increased significantly with acne severity ( P <.05 between GEA‐2 and GEA‐3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci . A significant reduction ( P <.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic.
Author Dreno, Brigitte
Henley, Jessica B.
Martin, Richard
Seité, Sophie
Khammari, Amir
Moyal, Dominique
Author_xml – sequence: 1
  givenname: Brigitte
  surname: Dreno
  fullname: Dreno, Brigitte
  organization: CIC, Inserm U892‐CNRS 6299
– sequence: 2
  givenname: Richard
  surname: Martin
  fullname: Martin, Richard
  organization: L'Oréal Research and Innovation
– sequence: 3
  givenname: Dominique
  surname: Moyal
  fullname: Moyal, Dominique
  organization: La Roche‐Posay Dermatological Laboratories
– sequence: 4
  givenname: Jessica B.
  surname: Henley
  fullname: Henley, Jessica B.
  organization: University of Colorado
– sequence: 5
  givenname: Amir
  surname: Khammari
  fullname: Khammari, Amir
  organization: CIC, Inserm U892‐CNRS 6299
– sequence: 6
  givenname: Sophie
  orcidid: 0000-0001-9335-4139
  surname: Seité
  fullname: Seité, Sophie
  email: sophie.seite@loreal.com
  organization: La Roche‐Posay Dermatological Laboratories
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28094874$$D View this record in MEDLINE/PubMed
https://inserm.hal.science/inserm-01807656$$DView record in HAL
BookMark eNp10cFO3DAQBmALUcFCOfACVaReqERgbCeOzQ3RBSqt1AOtxM1yHLuYJvZiJ9B9-xp24YBaX-by_aPxzB7a9sEbhA4xnOD8Ts2f7gRTItgWmmEGUAIj9TaagQBWsgbqXbSX0j0AbmhT76BdwkFUvKlm6PLmt_PF4HQMrQuDKZTvCqW9KR6n_peKLp0VN6Na3q36oIPWUzouVOHNU0ZjiEUOP-uP6INVfTIHm7qPfl7Of1xcl4vvV98uzhelrgRmZZ5HCE2tZkoTowTu2poYbAVhlRXQ6KZhtKLGipYYRlvVas6s7VhrORYdofvoeN33TvVyGd2g4koG5eT1-UI6n0wcJGAODavZI878aM2XMTxMJo1ycEmbvlfehClJzBmuaw6EZvr5Hb0PU_T5MxILijmnHCCrTxs1tYPp3kZ4XWgGp2uQF5pSNFZqN6rRBT9G5XqJQT6fTOaTyZeT5cSXd4nXpv-ym-5Prjer_0M5v_26TvwF4QCi0A
CitedBy_id crossref_primary_10_1111_jdv_15795
crossref_primary_10_34172_jhp_2024_48170
crossref_primary_10_1111_exd_13791
crossref_primary_10_1111_exd_13397
crossref_primary_10_3389_fimmu_2023_1324930
crossref_primary_10_1111_srt_13269
crossref_primary_10_1097_BRS_0000000000005117
crossref_primary_10_1002_admi_202102261
crossref_primary_10_1007_s00005_018_0528_4
crossref_primary_10_3389_fcimb_2022_834135
crossref_primary_10_3390_jcm9010168
crossref_primary_10_1016_j_bbrc_2022_06_068
crossref_primary_10_1111_exd_13545
crossref_primary_10_1111_lam_13333
crossref_primary_10_2174_0126667797285930240306190539
crossref_primary_10_3390_microorganisms8111752
crossref_primary_10_1111_exd_13934
crossref_primary_10_1186_s12866_022_02477_2
crossref_primary_10_1186_s12934_022_01901_6
crossref_primary_10_25259_IJDVL_539_2024
crossref_primary_10_2147_CCID_S322876
crossref_primary_10_1007_s13555_024_01294_x
crossref_primary_10_13181_mji_v28i1_2735
crossref_primary_10_2174_0126667797276773231215053914
crossref_primary_10_1016_j_jddst_2023_104149
crossref_primary_10_1111_jdv_20203
crossref_primary_10_1016_j_phymed_2022_154101
crossref_primary_10_3390_biomedicines10050931
crossref_primary_10_1016_j_meegid_2020_104209
crossref_primary_10_1007_s00248_022_02070_0
crossref_primary_10_3390_cosmetics10060150
crossref_primary_10_1111_exd_14105
crossref_primary_10_1016_j_heliyon_2024_e34549
crossref_primary_10_3390_ijms24032695
crossref_primary_10_3390_antibiotics12010145
crossref_primary_10_1038_s41598_022_25436_3
crossref_primary_10_3389_fimmu_2023_1151527
crossref_primary_10_3389_fmicb_2018_01459
crossref_primary_10_1007_s40257_020_00531_1
crossref_primary_10_3390_life11090962
crossref_primary_10_1051_e3sconf_202127103013
crossref_primary_10_1080_13102818_2021_1885992
crossref_primary_10_1080_09546634_2019_1628173
crossref_primary_10_1007_s12275_022_1520_6
crossref_primary_10_1111_jocd_16120
crossref_primary_10_1111_exd_14604
crossref_primary_10_1038_s41522_024_00512_w
crossref_primary_10_2174_0118743722279314240219091938
crossref_primary_10_12677_ACM_2023_1361468
crossref_primary_10_1002_lsm_23426
crossref_primary_10_1002_jsfa_12921
crossref_primary_10_1016_j_jdsct_2024_100041
crossref_primary_10_1016_j_jaad_2023_12_017
crossref_primary_10_1080_10837450_2022_2038620
crossref_primary_10_3389_fmed_2023_1196149
crossref_primary_10_26724_2079_8334_2018_4_66_75_80
crossref_primary_10_3390_jcm8070987
crossref_primary_10_1111_bjd_19461
crossref_primary_10_1177_12034754211037994
crossref_primary_10_1016_j_ijpharm_2020_119074
crossref_primary_10_2478_am_2024_0009
crossref_primary_10_1016_j_annder_2018_11_002
crossref_primary_10_3390_cosmetics8030088
crossref_primary_10_1186_s41232_022_00212_y
crossref_primary_10_3390_ph16010087
crossref_primary_10_1111_dth_15288
crossref_primary_10_2147_CCID_S474331
crossref_primary_10_12968_joan_2019_8_9_430
crossref_primary_10_1002_adfm_202421075
crossref_primary_10_2147_CCID_S379609
crossref_primary_10_3390_cosmetics9030055
crossref_primary_10_1111_jdv_17009
crossref_primary_10_3390_molecules29102394
crossref_primary_10_1111_exd_14433
crossref_primary_10_3389_fmicb_2022_1065386
crossref_primary_10_1111_exd_14951
crossref_primary_10_1155_2017_5095293
crossref_primary_10_21886_2308_6424_2023_11_3_118_130
crossref_primary_10_47419_bjbabs_v3i02_124
crossref_primary_10_3390_ijms22189846
crossref_primary_10_3389_fcimb_2025_1543616
crossref_primary_10_1002_jvc2_436
crossref_primary_10_1007_s11046_021_00586_6
crossref_primary_10_3390_microorganisms7110550
crossref_primary_10_1080_17512433_2020_1796637
crossref_primary_10_3389_fmicb_2018_02912
crossref_primary_10_3390_ijms232113071
crossref_primary_10_1016_j_jaad_2019_08_078
crossref_primary_10_3389_fcimb_2024_1307374
crossref_primary_10_3390_microorganisms9020303
crossref_primary_10_1111_exd_14779
crossref_primary_10_23736_S2724_5276_22_07010_0
crossref_primary_10_3390_microorganisms9112216
crossref_primary_10_21518_ms2023_264
crossref_primary_10_1007_s13555_022_00844_5
crossref_primary_10_1007_s00403_024_02836_1
crossref_primary_10_12688_f1000research_15659_1
crossref_primary_10_1080_14712598_2022_2089560
crossref_primary_10_1016_j_mucimm_2023_02_005
crossref_primary_10_1111_jdv_19540
crossref_primary_10_21518_2079_701X_2022_16_3_63_68
crossref_primary_10_4167_jbv_2017_47_3_165
crossref_primary_10_33667_2078_5631_2023_24_56_60
crossref_primary_10_1111_jdv_15043
crossref_primary_10_3390_app132112086
crossref_primary_10_3390_app14083505
crossref_primary_10_25279_sak_899794
crossref_primary_10_3839_jabc_2025_008
crossref_primary_10_1007_s12275_021_0647_1
crossref_primary_10_3389_fphar_2022_832088
crossref_primary_10_3390_pharmaceutics15082083
crossref_primary_10_1111_bcp_13662
crossref_primary_10_1111_exd_14535
crossref_primary_10_4103_ds_ds_28_22
crossref_primary_10_1016_j_jdermsci_2021_04_007
crossref_primary_10_1111_ijd_16220
crossref_primary_10_1186_s40168_018_0558_5
crossref_primary_10_1007_s40588_025_00243_2
Cites_doi 10.1126/science.1260144
10.1111/1346-8138.13149
10.1186/s12864-016-2489-5
10.1111/ijd.12609
10.1038/nrmicro2537
10.1111/ajd.12253
10.1016/j.jid.2015.12.024
10.1128/JCM.00799-08
10.4049/jimmunol.169.3.1535
10.1111/exd.12206
10.1038/jid.2013.21
10.1111/j.1365-2133.1986.tb04060.x
10.1038/nature12171
10.1159/000087011
10.1007/s00253-013-5394-8
10.1111/bjd.14967
10.1093/bioinformatics/btq461
10.1128/AEM.00062-07
10.1186/gb-2012-13-11-r101
10.1111/1462-2920.12817
10.1126/science.1171700
10.1073/pnas.1000080107
10.12788/j.sder.0087
10.1155/2013/679680
10.1038/nmeth.2604
10.1371/journal.pone.0012277
10.1101/gr.096651.109
10.1016/j.jaad.2015.12.037
10.1590/0074-02760150356
10.1111/j.1468-3083.2010.03685.x
10.1159/000356777
10.1073/pnas.1424409112
10.1001/archderm.139.7.941-b
10.4103/0019-5154.174025
ContentType Journal Article
Copyright 2017 The Authors. Published by John Wiley & Sons Ltd
2017 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd.
2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: 2017 The Authors. Published by John Wiley & Sons Ltd
– notice: 2017 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd.
– notice: 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: Distributed under a Creative Commons Attribution 4.0 International License
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
NAPCQ
7X8
1XC
VOOES
DOI 10.1111/exd.13296
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE

MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1600-0625
EndPage 803
ExternalDocumentID oai_HAL_inserm_01807656v1
28094874
10_1111_exd_13296
EXD13296
Genre article
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: La Roche‐Posay Dermatological Laboratory
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
24P
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
CYRXZ
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
NAPCQ
7X8
1XC
VOOES
ID FETCH-LOGICAL-c4916-90699c3fc6ac2ea91db52e1f9264f907c776343ef9b2e63babc86ffd6bf819d23
IEDL.DBID DR2
ISSN 0906-6705
IngestDate Fri May 09 12:20:41 EDT 2025
Thu Jul 10 17:23:03 EDT 2025
Fri Jul 25 09:53:41 EDT 2025
Mon Jul 21 05:41:52 EDT 2025
Thu Apr 24 23:02:07 EDT 2025
Tue Jul 01 01:14:46 EDT 2025
Wed Jan 22 16:34:11 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords microbiota
Propionibacterium
diversity
acne
skin
microbiome
Staphylococcus
Language English
License Attribution-NonCommercial-NoDerivs
http://creativecommons.org/licenses/by-nc-nd/4.0
2017 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4916-90699c3fc6ac2ea91db52e1f9264f907c776343ef9b2e63babc86ffd6bf819d23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-9335-4139
0000-0001-9328-8004
0000-0001-5574-5825
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.13296
PMID 28094874
PQID 1931883800
PQPubID 2045157
PageCount 6
ParticipantIDs hal_primary_oai_HAL_inserm_01807656v1
proquest_miscellaneous_1861558023
proquest_journals_1931883800
pubmed_primary_28094874
crossref_citationtrail_10_1111_exd_13296
crossref_primary_10_1111_exd_13296
wiley_primary_10_1111_exd_13296_EXD13296
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2017
PublicationDateYYYYMMDD 2017-09-01
PublicationDate_xml – month: 09
  year: 2017
  text: September 2017
PublicationDecade 2010
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Chichester
PublicationTitle Experimental dermatology
PublicationTitleAlternate Exp Dermatol
PublicationYear 2017
Publisher Wiley Subscription Services, Inc
Wiley
Publisher_xml – name: Wiley Subscription Services, Inc
– name: Wiley
References 2015; 56
2015; 14
1986; 114
2003; 139
2013; 22
2005; 211
2016; 74
2011; 10
2005
2007; 73
2016; 18
2012; 202
2016; 17
2012; 13
2016; 12
2011; 9
2014; 228
2011; 108
2010; 26
2013; 10
2013; 2013
2002; 169
2015; 112
2016; 43
2013; 133
2016; 111
2009; 8
2013; 498
2008; 46
2016
2016; 61
2011; 25
2016; 136
2009; 19
2010; 5
2009; 324
2014; 346
2014; 33
2014; 98
2014; 53
e_1_2_7_6_1
Sanchez D. A. (e_1_2_7_5_1) 2015; 14
e_1_2_7_3_1
e_1_2_7_7_1
Domizio J. (e_1_2_7_4_1) 2016; 12
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
Bellew S. (e_1_2_7_8_1) 2011; 10
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
Chikviladze D. P. (e_1_2_7_41_1) 2012; 202
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
Wilson M. (e_1_2_7_30_1) 2005
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_38_1
e_1_2_7_39_1
Bhambri S. (e_1_2_7_9_1) 2009; 8
References_xml – volume: 33
  start-page: 98
  year: 2014
  publication-title: Semin. Cutan. Med. Surg.
– volume: 74
  start-page: e933
  year: 2016
  publication-title: J. Am. Acad. Dermatol.
– volume: 43
  start-page: 406
  year: 2016
  publication-title: J. Dermatol.
– volume: 202
  start-page: 60
  year: 2012
  publication-title: Georgian Med. News
– volume: 108
  start-page: 4516
  issue: Suppl. 1
  year: 2011
  publication-title: Proc. Natl Acad. Sci. USA
– year: 2005
– volume: 73
  start-page: 5261
  year: 2007
  publication-title: Appl. Environ. Microbiol.
– volume: 136
  start-page: 621
  year: 2016
  publication-title: J. Invest. Dermatol.
– volume: 8
  start-page: 615
  year: 2009
  publication-title: J. Drugs Dermatol.
– volume: 5
  start-page: e12277
  year: 2010
  publication-title: PLoS ONE
– volume: 114
  start-page: 535
  year: 1986
  publication-title: Br. J. Dermatol.
– volume: 13
  start-page: R101
  year: 2012
  publication-title: Genome Biol.
– volume: 46
  start-page: 3355
  year: 2008
  publication-title: J. Clin. Microbiol.
– volume: 61
  start-page: 45
  year: 2016
  publication-title: Indian J. Dermatol.
– volume: 26
  start-page: 2460
  year: 2010
  publication-title: Bioinformatics
– volume: 56
  start-page: 268
  year: 2015
  publication-title: Australas. J. Dermatol.
– volume: 112
  start-page: E2120
  year: 2015
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 228
  start-page: 86
  year: 2014
  publication-title: Dermatology
– volume: 14
  start-page: 127
  year: 2015
  publication-title: J. Drugs Dermatol.
– volume: 211
  start-page: 193
  year: 2005
  publication-title: Dermatology
– volume: 22
  start-page: 587
  year: 2013
  publication-title: Exp. Dermatol.
– volume: 18
  start-page: 1686
  year: 2016
  publication-title: Environ. Microbiol.
– volume: 9
  start-page: 244
  year: 2011
  publication-title: Nat. Rev. Microbiol.
– volume: 12
  start-page: 660
  year: 2016
  publication-title: Rev. Med. Suisse
– year: 2016
  publication-title: Br. J. Dermatol.
– volume: 19
  start-page: 2317
  year: 2009
  publication-title: Genome Res.
– volume: 10
  start-page: 582
  year: 2011
  publication-title: J. Drugs Dermatol.
– volume: 25
  start-page: 43
  year: 2011
  publication-title: J. Eur. Acad. Dermatol. Venereol.
– volume: 10
  start-page: 996
  year: 2013
  publication-title: Nat. Methods
– volume: 17
  start-page: 152
  year: 2016
  publication-title: BMC Genom.
– volume: 98
  start-page: 411
  year: 2014
  publication-title: Appl. Microbiol. Biotechnol.
– volume: 133
  start-page: 2152
  year: 2013
  publication-title: J. Invest. Dermatol.
– volume: 139
  start-page: 941
  year: 2003
  publication-title: Arch. Dermatol.
– volume: 111
  start-page: 155
  year: 2016
  publication-title: Mem. Inst. Oswaldo Cruz
– volume: 53
  start-page: 1177
  year: 2014
  publication-title: Int. J. Dermatol.
– volume: 498
  start-page: 367
  year: 2013
  publication-title: Nature
– volume: 346
  start-page: 954
  year: 2014
  publication-title: Science
– volume: 324
  start-page: 1190
  year: 2009
  publication-title: Science
– volume: 2013
  start-page: 679680
  year: 2013
  publication-title: Biomed. Res. Int.
– volume: 169
  start-page: 1535
  year: 2002
  publication-title: J. Immunol.
– ident: e_1_2_7_18_1
  doi: 10.1126/science.1260144
– ident: e_1_2_7_38_1
  doi: 10.1111/1346-8138.13149
– ident: e_1_2_7_21_1
  doi: 10.1186/s12864-016-2489-5
– ident: e_1_2_7_19_1
  doi: 10.1111/ijd.12609
– ident: e_1_2_7_2_1
  doi: 10.1038/nrmicro2537
– ident: e_1_2_7_6_1
  doi: 10.1111/ajd.12253
– ident: e_1_2_7_33_1
  doi: 10.1016/j.jid.2015.12.024
– ident: e_1_2_7_32_1
  doi: 10.1128/JCM.00799-08
– volume: 8
  start-page: 615
  year: 2009
  ident: e_1_2_7_9_1
  publication-title: J. Drugs Dermatol.
– ident: e_1_2_7_10_1
  doi: 10.4049/jimmunol.169.3.1535
– ident: e_1_2_7_12_1
  doi: 10.1111/exd.12206
– ident: e_1_2_7_13_1
  doi: 10.1038/jid.2013.21
– ident: e_1_2_7_15_1
  doi: 10.1111/j.1365-2133.1986.tb04060.x
– ident: e_1_2_7_31_1
  doi: 10.1038/nature12171
– ident: e_1_2_7_11_1
  doi: 10.1159/000087011
– ident: e_1_2_7_22_1
  doi: 10.1007/s00253-013-5394-8
– ident: e_1_2_7_7_1
  doi: 10.1111/bjd.14967
– volume: 14
  start-page: 127
  year: 2015
  ident: e_1_2_7_5_1
  publication-title: J. Drugs Dermatol.
– ident: e_1_2_7_27_1
  doi: 10.1093/bioinformatics/btq461
– ident: e_1_2_7_28_1
  doi: 10.1128/AEM.00062-07
– ident: e_1_2_7_34_1
  doi: 10.1186/gb-2012-13-11-r101
– ident: e_1_2_7_24_1
  doi: 10.1111/1462-2920.12817
– ident: e_1_2_7_3_1
  doi: 10.1126/science.1171700
– ident: e_1_2_7_25_1
  doi: 10.1073/pnas.1000080107
– ident: e_1_2_7_29_1
  doi: 10.12788/j.sder.0087
– ident: e_1_2_7_36_1
  doi: 10.1155/2013/679680
– ident: e_1_2_7_26_1
  doi: 10.1038/nmeth.2604
– volume-title: Microbial Inhabitants of Humans: Their Ecology and Role in Health and Disease
  year: 2005
  ident: e_1_2_7_30_1
– ident: e_1_2_7_14_1
  doi: 10.1371/journal.pone.0012277
– ident: e_1_2_7_20_1
  doi: 10.1101/gr.096651.109
– volume: 10
  start-page: 582
  year: 2011
  ident: e_1_2_7_8_1
  publication-title: J. Drugs Dermatol.
– volume: 12
  start-page: 660
  year: 2016
  ident: e_1_2_7_4_1
  publication-title: Rev. Med. Suisse
– ident: e_1_2_7_37_1
  doi: 10.1016/j.jaad.2015.12.037
– ident: e_1_2_7_40_1
  doi: 10.1590/0074-02760150356
– ident: e_1_2_7_23_1
  doi: 10.1111/j.1468-3083.2010.03685.x
– ident: e_1_2_7_35_1
  doi: 10.1159/000356777
– volume: 202
  start-page: 60
  year: 2012
  ident: e_1_2_7_41_1
  publication-title: Georgian Med. News
– ident: e_1_2_7_17_1
  doi: 10.1073/pnas.1424409112
– ident: e_1_2_7_16_1
  doi: 10.1001/archderm.139.7.941-b
– ident: e_1_2_7_39_1
  doi: 10.4103/0019-5154.174025
SSID ssj0017375
Score 2.5215094
Snippet Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This...
Propionibacterium acnes ( P. acnes ), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne....
Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This...
SourceID hal
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 798
SubjectTerms Acne
Acne Vulgaris - drug therapy
Acne Vulgaris - microbiology
Adolescent
Adult
Anti-Bacterial Agents - administration & dosage
Cancer
Comedones
diversity
Double-Blind Method
Erythromycin
Erythromycin - administration & dosage
Female
Fish
Humans
Keratinocytes
Life Sciences
Male
microbiome
microbiota
Microbiota - drug effects
Next-generation sequencing
Propionibacterium
rRNA 16S
Sebaceous gland
Skin
Skin - microbiology
Skin diseases
Staphylococcus
Staphylococcus - isolation & purification
Young Adult
Title Skin microbiome and acne vulgaris: Staphylococcus, a new actor in acne
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.13296
https://www.ncbi.nlm.nih.gov/pubmed/28094874
https://www.proquest.com/docview/1931883800
https://www.proquest.com/docview/1861558023
https://inserm.hal.science/inserm-01807656
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB_aPogvWr9Xa4mi4IN77CbZ3USfivY4xIqIhXsQlnzSQ2-v9G5L6V_fSfYD6weIbwuZsNlMJvObzeQ3AC8ctSU6ZpYan_GUS8dSyU2RKs68zRSVPvJsH30qZ8f8w7yYb8Hb4S5Mxw8x_nALlhH362DgSq9_MnJ3YSehSnqg2w65WgEQfRmpo_KKRZLdTGLEXFZZ0bMKhSyesec1X7R9EjIhf4eZ11FrdDvT2_BtGHCXbfJ90m70xFz-wuX4n1-0C7d6OEoOuvVzB7ZccxduHPUH7vdgGopzkeWio2taOqIaS5RpHDlvwyWQxfoNQbyKukKnuDKmXb8miiBUJ7GOD8HOQfo-HE8Pv76bpX3phdRwBIwpzpqUhnlTKkOdkrnVBXW5l4ifPMbTpsJ9iTPnpaauZFppI0rvbak9QgxL2QPYaVaNewSkEtqKQmMgZjTPOFeMYSRcFNbluhBUJvBqUEJtel7yUB7jRz3EJzgvdZyXBJ6PoqcdGcefhF6iJsf2QJ89O_hYLxo06WUd-MoqxLDneQJ7g67r3m7XNcLZXAiGKDqBZ2MzWlw4RlGNW7UoI8JZbiDOS-Bht0bGt1GB4bKoOH5U1PTfh1kfzt_Hh8f_LvoEbtKAKmKK2x7sbM5a9xQx0Ubvwzbln_ejCVwBM_wFHg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD60FdQX79bRqlEUfHCWmUnmEvGl2C6r7vZBWtgXCbnSRXe2dHeK-Os9yVywXkB8G8gJk-TkJN9JTr4D8MJmpsCNmcbaJSxm3NKYM53HklFnEplxF3i2Z0fF5IR9mOfzLXjbv4Vp-SGGAzdvGWG99gbuD6R_snL7zYx8mvRiG674jN6eOf_g00AelZY00OwmHH3mokzyjlfIx_EMVS_tRtunPhbyd6B5GbeGjWd8Ez73TW7jTb6Mmo0a6e-_sDn-b59uwY0OkZL9dgrdhi1b34Grs-7O_S6MfX4usly0jE1LS2RtiNS1JReNfweyWL8hCFlRXbgvrrRu1q-JJIjWSUjlQ7Cyl74HJ-PD43eTuMu-EGuGmDHGYeNcU6cLqTMreWpUntnUcYRQDl1qXeLSxKh1XGW2oEoqXRXOmUI5RBkmo_dhp17V9gGQslKmyhX6YlqxhDFJKTrDeW5sqvIq4xG86rUgdEdN7jNkfBW9i4LjIsK4RPB8ED1r-Tj-JPQSVTmUewbtyf5ULGq06qXwlGUlwtiLNIK9XtmiM921QESbVhVFIB3Bs6EYjc7fpMjarhqUqfx1rufOi2C3nSTD37IKPeaqZNipoOq_N1Mczg_Cx8N_F30K1ybHs6mYvj_6-AiuZx5khIi3PdjZnDf2MUKkjXoSLOEHXCsIYw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB71IVVcKigFAqWYikocCEpsJ7HhVLVdLfShHqi0N8tPsRKbrbrdip_P2MlGVIDELZLHSjKTsb_JjL8BeOepq3FjZrkNBc-59CyX3Fa55iy4QlMZEs_2xWU9vuZfJ9VkDT6vzsJ0_BDDD7foGWm9jg5-48JvTu5_uo-xS3q9Dpsx2RfruSi_GlIIDUssu4XEkLluiqqnFYplPMPUB5vR-vdYCvknznwIW9O-M3oM2z1gJEedhZ_Amm93YOuiT4k_hVFsn0Vm045QaeaJbh3RtvXkfhmPaUwXnwgiStQmbltza5eLD0QTBNMkddohODlK78L16PTb8TjvmyPkliOky_G1pLQs2Fpb6rUsnamoL4NEhBMw4rUNrhyc-SAN9TUz2lhRh-BqExAEOMqewUY7b_0LII0wTlQGQyVreMG5Zgxj1apyvjSVoDKD9ystKdszh8cGFj_UKoJAhaqk0AwOBtGbji7jb0KHqOphPBJcj4_O1bRFp5upyCjWIMq8LzPYWxlD9Z61UAg4SyEY4twM3g7D6BMx0aFbP1-ijIjZ1khtl8HzzojD3ajAgFY0HF8qWfXfj6lOJyfp4uX_i76BrauTkTr_cnn2Ch7RCAFSPdoebNzdLv1rBDB3Zj99qL8AOcbmyw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Skin+microbiome+and+acne+vulgaris%3A+Staphylococcus%2C+a+new+actor+in+acne&rft.jtitle=Experimental+dermatology&rft.au=Dreno%2C+Brigitte&rft.au=Martin%2C+Richard&rft.au=Moyal%2C+Dominique&rft.au=Henley%2C+Jessica+B.&rft.date=2017-09-01&rft.issn=0906-6705&rft.eissn=1600-0625&rft.volume=26&rft.issue=9&rft.spage=798&rft.epage=803&rft_id=info:doi/10.1111%2Fexd.13296&rft.externalDBID=10.1111%252Fexd.13296&rft.externalDocID=EXD13296
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0906-6705&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0906-6705&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0906-6705&client=summon